In bladder cancers, a multiple regional epigenetic silencing phenotype was found to occur in a subset of aggressive tumors of the carcinoma in situ pathway but not in tumors driven by mutations in FGFR3 [17]. This evidence concerns the gene FGFR3 and urinary bladder cancer.